$BRO

Brown & Brown GAAP EPS of $1.07 beats by $0.28, revenue of $1.7B misses by $60M (NYSE:BRO)

Brown & Brown (BRO) reported Q3 GAAP EPS of $1.07, beating estimates by $0.28, while revenue of $1.7B missed by $60M. Revenue grew 5.6% year-over-year. The stock fell 1.52% in after-hours trading.

Original reporting
Published Oct 26, 2026, 9:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BRO
Neutral
high confidence
Mentioned
$BRO
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$BRONeutralMed
01

Why it matters

The earnings release provides new data that can influence short‑term price action; the mixed results suggest a nuanced market reaction.

02

Market read

First report of Q3 earnings with both an EPS beat and revenue miss; relevant for traders monitoring insurance sector performance.

03

What to watch

Potential upside from recent acquisition activity that may not be reflected in the current quarter.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Brown & Brown is a U.S. insurance brokerage that reported Q3 results on Oct 26, 2026.

Company-level read

Ticker impact

$BRONeutralHigh confidence
Context

Q3 GAAP EPS of $1.07 beats expectations by $0.28 while revenue of $1.7B misses by $60M.

Expected impact

likely modest downside as investors price in the revenue shortfall despite the EPS beat

Evidence & confidence

The earnings release provides fresh numbers; the revenue miss is a negative catalyst that could offset the positive EPS surprise.

Market effects

Insurance brokerage sector may see mixed reactions as the beat on earnings is offset by slower top‑line growth.

U.S. market participants may adjust short‑term positioning in BRO and peer insurers.

Limited; impact confined to U.S. insurance and brokerage stocks.

Counterpoint

Revenue miss could be a buying opportunity if the market overreacts to the shortfall.

Key entities

  • Brown & Brown, Inc.

    U.S. insurance brokerage reporting Q3 earnings.

Related articles

$BROMed

Brown & Brown Inc (BRO) (Q3 2026) Earnings Call Highlights: Revenue Up 7.4%

Brown & Brown Inc (BRO) reported Q3 2026 revenue up 7.4% to $1.07B, but adjusted EBITDAC margin fell 200 bps to 34.6%. Specialty Distribution organic revenue declined 0.8%, missing expectations due to competition and pricing pressures. The company anticipates further declines in Q4 and faces ongoing litigation impacts. Integration costs for Accession have increased to $250-300M.

$BROMed

What Brown & Brown (BRO) Said on Its Q3 Earnings Call

Brown & Brown (BRO) reported Q3 earnings, noting market shifts in California and Texas, and pricing pressures in commercial earthquake business. The company expects 2027 growth of 2%-4% for retail and 1%-3% for specialty distribution. Accession acquisition raised synergy targets to $50M for 2026 and $175M by 2028. AI initiatives are expanding across the company, with tools like Claude and COMPASS being deployed. The board increased the dividend by 9%.

$BROHighAI 8/10

Brown & Brown (BRO) Q3 2026 Earnings Call Transcript

Brown & Brown (BRO) reported Q3 2026 revenues of $1.7B, up 7.4% YoY. Organic revenue grew 1.2%, while adjusted EBITDAC margin fell 200 bps to 34.6%. Adjusted EPS rose 2% to $1.07. The company raised its dividend by 9%, marking 33 consecutive years of increases. Retail segment outperformed expectations, while specialty distribution faced headwinds. The company repurchased $750M in shares YTD, including $250M in Q3.

$BROMed

Truist cuts Brown & Brown stock price target to $85 on lower estimates

Truist Securities reduced its price target for Brown & Brown (NYSE:BRO) to $85 from $90, citing lower 2026 and 2027 EPS estimates. The firm maintained a Buy rating, basing the target on a 14x multiple of its 2027 EBITDA estimate. BRO's Q3 earnings missed expectations, with revenue at $1.72B and EPS at $1.07, though both showed year-over-year growth. The company's organic growth slowed, and its adjusted EBITDAC margin declined by 200 basis points.

$BROMed

Why Brown & Brown (BRO) stock is trading lower today

Brown & Brown (BRO) shares fell 4.9% after reporting Q3 2026 revenue of $1.73B, up 7.4% YoY, but with slowing organic growth and margin compression. CEO Powell Brown noted declines in excess-and-surplus property rates and expected further decreases in 2027. The stock is down 13.4% YTD, trading at $67.25, 23.4% below its 52-week high.